Metagenomi Therapeutics
(NASDAQ) MGX
Metagenomi Therapeutics Financials at a Glance
Market Cap
$55.68M
Revenue (TTM)
$25.21M
Net Income (TTM)
$87.87M
EPS (TTM)
$-2.36
P/E Ratio
-0.63
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$1.49
Volume
4,235
Open
$1.49
Price
$1.49
Volume
4,235
Open
$1.49
Previous Close
$1.49
Daily Range
$1.48 - $1.52
52-Week Range
$1.25 - $3.95
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$1.49
Volume
4,235
Open
$1.49
Previous Close
$1.49
Daily Range
$1.48 - $1.52
52-Week Range
$1.25 - $3.95
MGX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Metagenomi Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
119
CEO
Jian Irish, PhD, MBA
Website
www.metagenomi.coHeadquarters
Emeryville, 94608, US
MGX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
-4%
Net Income Margin
-3%
Return on Equity
-45%
Return on Capital
-48%
Return on Assets
-40%
Earnings Yield
-1.59%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$55.68M
Shares Outstanding
37.62M
Volume
4.24K
Short Interest
0.00%
Avg. Volume
242.33K
Financials (TTM)
Gross Profit
$19.89M
Operating Income
$96.01M
EBITDA
$90.70M
Operating Cash Flow
$88.89M
Capital Expenditure
$574.00K
Free Cash Flow
$89.47M
Cash & ST Invst.
$160.80M
Total Debt
$40.66M
Metagenomi Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$3.91M
-59.3%
Gross Profit
$2.61M
-72.8%
Gross Margin
66.76%
N/A
Market Cap
$55.68M
N/A
Market Cap/Employee
$275.64K
N/A
Employees
202
N/A
Net Income
$22.53M
+3.7%
EBITDA
$23.07M
-20.4%
Quarterly Fundamentals
Net Cash
$120.14M
-40.7%
Accounts Receivable
$305.00K
-75.7%
Inventory
$0.00
N/A
Long Term Debt
$34.63M
-13.8%
Short Term Debt
$6.03M
+7.7%
Return on Assets
-39.74%
N/A
Return on Invested Capital
-48.45%
N/A
Free Cash Flow
$23.63M
+11.2%
Operating Cash Flow
$23.55M
+10.4%